Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Brown University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04129515CT.gov NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | — | Withdrawn | — | — | — |
NCT05669352CT.gov A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases | — | Suspended | — | — | — |
NCT06784648CT.gov Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT07436390CT.gov IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | — | Completed | — | — | — |
NCT05913388CT.gov GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | — | Recruiting | — | — | — |
NCT05304546CT.gov Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT04987996CT.gov GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | — | Withdrawn | — | — | — |
NCT05764395CT.gov Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | — | Active Not Recruiting | — | — | — |
NCT05727904CT.gov Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | — | Recruiting | — | — | — |
NCT04616248CT.gov In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Show 52 more trialsShow fewer
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05155033CT.gov Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT05176470CT.gov Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT05155254CT.gov IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07422779CT.gov Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | — | Recruiting | — | — | — |
NCT04955743CT.gov Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05034536CT.gov PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT04930783CT.gov NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | — | Active Not Recruiting | — | — | — |
NCT07376317CT.gov Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) | — | Active Not Recruiting | — | — | — |
NCT04697576CT.gov Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | — | Recruiting | — | — | — |
NCT04703426CT.gov Sargramostim (GM-CSF) + PD-1 | — | Withdrawn | — | — | — |
NCT04633902CT.gov Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | — | Unknown | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT05611229CT.gov Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | Completed | — | — | — |
NCT04152863CT.gov Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | — | Terminated | — | — | — |
NCT03773744CT.gov MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma | — | Withdrawn | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03957551CT.gov Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | — | Terminated | — | — | — |
NCT03875079CT.gov A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma | — | Completed | — | — | — |
NCT03474497CT.gov UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | — | Active Not Recruiting | — | — | — |
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03873818CT.gov Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | — | Completed | — | — | — |
NCT03684785CT.gov Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03534635CT.gov Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | — | Unknown | — | — | — |
NCT03265080CT.gov A Study of ADXS-NEO Expressing Personalized Tumor Antigens | — | Terminated | — | — | — |
NCT03276832CT.gov Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | — | Completed | — | — | — |
NCT03149029CT.gov Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | — | Active Not Recruiting | — | — | — |
NCT03200847CT.gov Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | — | Completed | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03131908CT.gov Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | — | Active Not Recruiting | — | — | — |
NCT02748564CT.gov Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT02816021CT.gov Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT03021460CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02740920CT.gov Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | — | Terminated | — | — | — |
NCT02990416CT.gov A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | — | Unknown | — | — | — |
NCT02858869CT.gov Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | — | Completed | — | — | — |
NCT02791594CT.gov Imaging FDG Flare in Melanoma | — | Completed | — | — | — |
NCT02617849CT.gov Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | — | Unknown | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02676869CT.gov Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
NCT02625337CT.gov Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients | — | Unknown | — | — | — |
NCT02506153CT.gov Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02521870CT.gov A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | — | Terminated | — | — | — |
NCT02500576CT.gov Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02298959CT.gov Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | — | Active Not Recruiting | — | — | — |
NCT02306850CT.gov Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | — | Completed | — | — | — |
NCT02073123CT.gov Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02054520CT.gov Immunotherapy Study for Patients With Stage IV Melanoma | — | Terminated | — | — | — |
NCT01993719CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Brown University | P3 | B · 62 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →